Verona Pharma plc (NASDAQ:VRNA) CEO Sells $12,000.00 in Stock

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 2,400 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $5.00, for a total value of $12,000.00. Following the completion of the transaction, the chief executive officer now owns 15,202,352 shares of the company’s stock, valued at $76,011,760. This represents a 0.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

David Zaccardelli also recently made the following trade(s):

• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The stock was sold at an average price of $4.39, for a total value of $413,292.16.
• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $1,076,533.92.

Verona Pharma Trading Down 4.2 %

Shares of Verona Pharma stock opened at $35.37 on Friday. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93. The stock’s fifty day moving average is $32.42 and its two-hundred day moving average is $23.40. Verona Pharma plc has a 52 week low of $11.39 and a 52 week high of $40.13.

Verona Pharma (NASDAQ:VRNA) last issued its earnings results on Monday, November 4th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The business had revenue of $5.62 million during the quarter, compared to analyst estimates of $2.31 million. During the same period last year, the company earned ($0.18) EPS. Sell-side analysts predict that Verona Pharma plc will post -2.11 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in Verona Pharma by 25.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock valued at $75,000 after acquiring an additional 529 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Verona Pharma by 70.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock valued at $38,000 after purchasing an additional 553 shares during the last quarter. CWM LLC acquired a new stake in shares of Verona Pharma in the 2nd quarter worth $29,000. EMC Capital Management purchased a new position in Verona Pharma during the 2nd quarter worth $38,000. Finally, Sei Investments Co. increased its position in Verona Pharma by 3.7% during the 1st quarter. Sei Investments Co. now owns 74,294 shares of the company’s stock valued at $1,195,000 after buying an additional 2,640 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on VRNA. Truist Financial raised their target price on Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Wells Fargo & Company raised their price objective on shares of Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Canaccord Genuity Group upped their target price on shares of Verona Pharma from $37.00 to $44.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, HC Wainwright lifted their price target on shares of Verona Pharma from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $43.83.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.